{"ATC Code":"G03AC06; G03DA02","Abbreviation":"MPA","Aliases":["Medroxyprogesterone 17-acetate","Provera","Depo-Provera","Metigestrona","Gestapuran","Perlutex","Veramix","Methylacetoxyprogesterone","Medroxyacetate progesterone","Depcorlutin"],"Biological Half-Life":"Oral medroxyprogesterone acetate (MPA) has an absorption half life of 15-30min and a biological half life of 40-60 hours. Intramuscular MPA has an absorption half life of 0.86±0.30 days and an elimination half life of 24.03±21.74 days. Subcutaneous MPA has an absorption half life of 1.05±0.56 days and an elimination half life of 30.90±15.11 days.","CAS":"71-58-9","CanonicalSMILES":"CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C","ChEBI":"CHEBI:6716","ChEMBL":"CHEMBL717","ChemicalClasses":["steroid"],"Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Hormones; Progesterone Congeners","Drug Indication":"Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology. Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy. Subcutaneous MPA is indicated to prevent pregnancy and manage pain associated with endometriosis. Intramuscular MPA is indicated to prevent pregnancy, and at higher concentrations for palliative treatment of endometrial or renal carcinoma.","DrugClasses":["hormone"],"European Community (EC) Number":"200-757-9","FDA Pharmacological Classification":"MEDROXYPROGESTERONE ACETATE","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Contraceptive Agents, Female; Contraceptives, Oral, Synthetic; Hormones; Progesterone Congeners","IUPACName":"[(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate","InChI":"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1","InChIKey":"PSGAAPLEWMOORI-PEINSRQWSA-N","MeSH Pharmacological Classification":"Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading. (See all compounds classified as Contraceptive Agents, Male.)","Melting Point":"405 to 408 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e24\u003c/sub\u003eH\u003csub\u003e34\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"386.5 g/mol","Pharmacodynamics":"Medroxyprogesterone acetate (MPA) inhibits gonadotropin production, reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium, and induces p53 dependant apoptosis in cancer cell lines. MPA oral tablets have a half life of 40-60 hours and other formulations can have half lives that are considerably longer, so the duration of action is long. The therapeutic window is wide as patients may take doses ranging from 5mg orally daily to 1000mg as a depo injection weekly. Long term use of MPA is associated with a reduction in bone density and patients who taking MPA during adolescence may have lower peak bone mass than untreated patients, which can also increase the risk of osteoporosis and fractures in the future.","Physical Description":"Medroxyprogesterone acetate is an odorless white to off-white microcrystalline powder. (NTP, 1992)","PubChemId":6279,"Record Description":["Medroxyprogesterone Acetate can cause cancer according to The World Health Organization's International Agency for Research on Cancer (IARC). It can cause developmental toxicity according to state or federal government labeling requirements.","Medroxyprogesterone acetate is an odorless white to off-white microcrystalline powder. (NTP, 1992)","Medroxyprogesterone acetate is an acetate ester resulting from the formal condensation of the 17alpha-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control. It has a role as a progestin, an androgen, a female contraceptive drug, a synthetic oral contraceptive, an adjuvant, an inhibitor, an antioxidant and an antineoplastic agent. It is a steroid ester, an acetate ester, a 20-oxo steroid, a 3-oxo-Delta(4) steroid and a corticosteroid. It is functionally related to a medroxyprogesterone.","Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.  Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.","Medroxyprogesterone Acetate is a synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","MEDROXYPROGESTERONE ACETATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 6 approved and 26 investigational indications. This drug has a black box warning from the FDA.","Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17‘±-hydroxy-6‘±-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. ","A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.","See also: Medroxyprogesterone (has active moiety); Estrogens, conjugated; medroxyprogesterone acetate (component of); Estradiol cypionate; medroxyprogesterone acetate (component of).","Medroxyprogesterone Acetate can cause cancer according to The World Health Organization's International Agency for Research on Cancer (IARC). It can cause developmental toxicity according to state or federal government labeling requirements.","Medroxyprogesterone acetate is an acetate ester resulting from the formal condensation of the 17alpha-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control. It has a role as a progestin, an androgen, a female contraceptive drug, a synthetic oral contraceptive, an adjuvant, an inhibitor, an antioxidant and an antineoplastic agent. It is a steroid ester, an acetate ester, a 20-oxo steroid, a 3-oxo-Delta(4) steroid and a corticosteroid. It is functionally related to a medroxyprogesterone."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Medroxyprogesterone_acetate"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q2823834"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00603"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/6279"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.29272082.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL717"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6716"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=71-58-9"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C08150"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/C2QI4IOI2G"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0025527"}],"Solubility":"less than 1 mg/mL at 73 °F (NTP, 1992)","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="114.264mm" version="1.2" viewBox="0 0 125.801 114.264" width="125.801mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="115.0" stroke="none" width="126.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="55.64" x2="55.64" y1="113.354" y2="98.114"/>
                  
            <line class="bond" id="mol1bnd2" x1="55.64" x2="68.848" y1="98.114" y2="90.494"/>
                  
            <line class="bond" id="mol1bnd3" x1="68.848" x2="68.848" y1="90.494" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd4" x1="68.848" x2="55.64" y1="75.254" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd5" x1="55.64" x2="55.64" y1="67.634" y2="52.394"/>
                  
            <line class="bond" id="mol1bnd6" x1="55.64" x2="68.848" y1="52.394" y2="44.774"/>
                  
            <line class="bond" id="mol1bnd7" x1="68.848" x2="82.056" y1="44.774" y2="52.394"/>
                  
            <line class="bond" id="mol1bnd8" x1="82.056" x2="82.056" y1="52.394" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd9" x1="68.848" x2="82.056" y1="75.254" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd10" x1="82.056" x2="96.585" y1="67.634" y2="72.307"/>
                  
            <line class="bond" id="mol1bnd11" x1="96.585" x2="105.526" y1="72.307" y2="60.014"/>
                  
            <line class="bond" id="mol1bnd12" x1="105.526" x2="96.585" y1="60.014" y2="47.72"/>
                  
            <line class="bond" id="mol1bnd13" x1="82.056" x2="96.585" y1="52.394" y2="47.72"/>
                  
            <line class="bond" id="mol1bnd14" x1="96.585" x2="109.788" y1="47.72" y2="40.109"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="109.789" x2="120.309" y1="38.701" y2="44.784"/>
                        
                <line x1="108.569" x2="119.088" y1="40.812" y2="46.895"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="120.309" x2="115.049" y1="44.784" y2="41.7425"/>
                <line class="hi" stroke="#FF0D0D" x1="119.088" x2="113.82849999999999" y1="46.895" y2="43.8535"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="109.788" x2="109.798" y1="40.109" y2="24.869"/>
                  
            <line class="bond" id="mol1bnd17" x1="96.585" x2="90.039" y1="47.72" y2="32.947"/>
                  
            <line class="bond" id="mol1bnd18" x1="90.758" x2="97.416" y1="26.144" y2="17.015"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="96.586" x2="91.731" y1="18.152" y2="7.194"/>
                        
                <line x1="98.816" x2="93.96" y1="17.164" y2="6.206"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="91.731" x2="94.1585" y1="7.193999999999999" y2="12.673"/>
                <line class="hi" stroke="#FF0D0D" x1="93.96" x2="96.388" y1="6.2059999999999995" y2="11.685"/>
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="97.416" x2="112.569" y1="17.015" y2="18.635"/>
                  
            <line class="bond" id="mol1bnd21" x1="82.056" x2="83.669" y1="52.394" y2="37.239"/>
                  
            <line class="bond" id="mol1bnd22" x1="55.64" x2="42.432" y1="67.634" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd23" x1="42.432" x2="42.432" y1="75.254" y2="90.494"/>
                  
            <line class="bond" id="mol1bnd24" x1="55.64" x2="42.432" y1="98.114" y2="90.494"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="29.224" x2="42.432" y1="98.114" y2="90.494"/>
                        
                <line x1="29.224" x2="39.994" y1="95.299" y2="89.086"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="29.224" x2="16.016" y1="98.114" y2="90.494"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="17.236" x2="6.707" y1="91.197" y2="97.279"/>
                        
                <line x1="16.016" x2="5.487" y1="89.086" y2="95.167"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="97.279" y2="94.238"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="95.167" y2="92.1265"/>
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="16.016" x2="16.016" y1="90.494" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd29" x1="16.016" x2="29.224" y1="75.254" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd30" x1="42.432" x2="29.224" y1="75.254" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd31" x1="42.432" x2="42.432" y1="75.254" y2="60.014"/>
                  
            <path class="atom" d="M125.241 47.735q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM121.377 47.735q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M90.695 29.325q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM86.831 29.325q.0 .923 .387 1.459q.393 .529 1.221 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.227 .523q-.393 .524 -.393 1.453z" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M93.501 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM89.638 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.386 -.536 .386 -1.459q.0 -.929 -.386 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm18" stroke="none"/>
                  
            <path class="atom" d="M5.078 98.113q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 98.113q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm25" stroke="none"/>
                
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="90.039" x2="93.312" y1="32.947" y2="40.3335"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="90.758" x2="94.08699999999999" y1="26.144" y2="21.5795"/>
        </g>
          
    </g>
    
</svg>
","Title":"Medroxyprogesterone acetate","UNII":"C2QI4IOI2G","Wikidata":"Q2823834","XLogP":4.1}